JonesResearch raised the firm’s price target on Lantheus to $128 from $114 and keeps a Buy rating on the shares. The company continued its solid commercial execution in Q4 and the market underappreciates its opportunities for expansion, the analyst tells investors in a research note. The firm believes the market is overly focused on Lantheus’ near-term quarterly results and not focused enough on broader industry trends and pipeline potential. It thinks the company will be successful in its efforts to dramatically expand both its therapeutic and imaging radiopharmaceutical product lines within the next two to five years.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LNTH:
- Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
- Lantheus sees Q1 adjusted EPS $1.50-$1.54, consensus $1.51
- Lantheus sees FY24 adjusted EPS $6.50-$6.70, consensus $6.25
- Lantheus reports Q4 adjusted EPS $1.75, consensus $1.45
- Is LNTH a Buy, Before Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue